Solid Biosciences (SLDB) FCF Margin (2021 - 2022)
Solid Biosciences (SLDB) posted FCF Margin of 275.8% for Q2 2022, up 80.61% sequentially from 1422.03% in Q1 2022, and up 21040.0% YoY from N/an in Q2 2021.
Powered by 
Analysis
Solid Biosciences (SLDB) FCF Margin (2021 - 2022) Analysis & Trends
Solid Biosciences has reported FCF Margin for 2 years, with the latest figure at 275.8% in Q2 2022.
- Quarterly FCF Margin rose 21040.0% year-over-year to 275.8% in Q2 2022, while the trailing twelve-month figure through Mar 2023 was 1615.03% (down 92816.0% YoY) and the FY2022 annual result came in at 1217.0%, down 64528.0% from the prior year.
- FCF Margin advanced to 275.8% in Q2 2022 per SLDB's latest filing, from 1422.03% in the prior quarter.
- Over five years, FCF Margin peaked at 275.8% in Q2 2022 and troughed at 1422.03% in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -274.50% |
| Mar 31, 2022 | -1,426.18% |
| Dec 31, 2021 | -682.75% |
| Sep 30, 2021 | -527.59% |
| Jun 30, 2021 | -485.50% |
| Mar 31, 2021 | -641.71% |